




Measure What Matters

Non-Communicable Diseases (NCDs)
are the largest cause of death





80%
are preventable

~1 in 3
die prematurely
(before 70)



Prevention fails widespread adoption because **current screening tools are invasive, fragmented, expensive and clinically limited**





Heart Rate




A diagram illustrating a neural network architecture. On the left, a blue circular region contains a white wavy line representing a continuous function. Five red dots are placed along this curve. To the right of the curve is a vertical bracket enclosing a column of five light blue circles, representing a hidden layer. To the right of the hidden layer is a column of five white circles, representing the output layer. A dense network of thin white lines connects the hidden layer nodes to the output layer nodes, representing the weights of the connections. A small black arrow points towards the top left of the blue circle.

5 Clinical Studies (2 active) | 3,900+ patients | 152+ variables




FDA: $\pm 15\text{-}20$ mg/dL



Glucose

Absorbance & Rotation


FDA: $\pm 5\text{-}8$ mmHg



Blood Pressure

PPG, Velocity & Acceleration


FDA: 3%



SpO2

Absorbance Ratios

FDA: ± 5 BPM



Heart Rate

Periodicity



Prediction & Prevention

Continuous Monitoring

Error¹ **6.4 - 15.7 mg/dL** *³
Accuracy² 97%

4.1 - 7.2 mmHg *
95%

0.9% *
95%

3.4 BPM *
95%


+27 Conditions
+19 Complications

* Preliminary results in controlled clinical settings / 1) Mean Absolute Error / 2) Calculated against gold-standard references / 3) Latest preliminary results obtained through cross-sectional and OGTT clinical studies across a broad glycemic range (49 - 489 mg/dL).


CDSS — Clinical Decision Support System

B2B H/SaaS $\geq$ \$550_{mo} + Licensing

- Hardware (Viit Gen-4)
- Software (Monitoring App & Admin)
- 4 Biomarkers & Cardio-Metabolic Risk
- Healthy Habits Lab (coach)
- Population-level Clinical Monitoring
- **\$350 upfront device fee**






Viit Health measures in **30 seconds for \$0.20** what traditionally takes over **17 minutes** and costs **\$15**



Healthy Habits Lab

- Coaching
- Reflections
- Content



Individual Reports

- Levels
- Trends
- Observations

Organizational Software

- Population Dashboard
- Anonymized risk stratification
- Longitudinal trend monitoring
- Segmentation by groups and locations

Technical & Clinical Support

- Anonymized individual profiles
- Clinical alerts and prioritization
- Reports and data export
- Secure integration with regulated EHR
- API integration with internal systems

PAM

TAM

SAM — \$119B

SOM — \$2.97B

- North America
- Latin America
- Geographic Focus

- Population Segments
- Primarily affected by NCDs

- 2.5% Penetration
- Active conversations (sectors)

\$780 B

\$338 B

Women

213K Org
348M Ind

Elders

158K Org
118M Ind

Children

255K Org
67M Ind

Underserved Communities

Public Health,
Prevention
& Personalized
Medicine Market



GO-TO-MARKET — Cardiometabolic Risk Observation Program (CROP - Paid Pilot)

Nov 2026 rollout
18 months
180 devices
20K participants
\$2.97M in revenue

Current Placement (MX)

Secured → **100** u
Reserved → **80** u



Top 10 largest organizations in Mexico



Partners

InBody
Body Composition

dailyhuman
Healthy Habits Lab

 **HOSPITAL GENERAL de MÉXICO**
DR. EDUARDO LICEAGA
Clinical Supervision

	General Use	Affordability	Accuracy	Readiness	Multi-Marker	Painless	Funding & Inc	 
							\$5,300,000 2017	
							\$70,000,000 2004	 HUAWEI
							\$30,000,000 2015	
							\$25,000,000 2017	 DEXCOM
KNOW LABS							\$12,000,000 2018	 Abbott
							\$1,5B 2013	
	Multiple markers — High Accuracy — Capital Efficiency & Low Cost — Population-Level Solution						Big Tech Support Flexibility	



Mayra Mora
MS - Arts et Métiers
Technology Director



Antonio García
PhD - UC.Berkeley
Science Director



Victoria Merino
MSE - U.Pennsylvania
Research Director



Fernando Gomez
Entrepreneur
Executive Director



Felix Agakov
PhD - U.Edinburgh
Artificial Intelligence



Adriana Monroy
MD/PhD - UNAM/UT
Clinical Research



Lorena de la Maza
MD - UNAM/Harvard Med
Medical Strategy




Luis Gomez
JD - Harvard Law
Corporate Affairs

Partners & Network



**Strong
Support**

**Unique
Information**



Relevant Recognitions



SECIHTI Grant



Initial Clinical Testing



Seed Round



Operational Break-even



Full Commercial Launch
(US & MX)



2017

2020

2022

2024

TRL 6 → 7


2026

Series A

2028



1st Prototype



SECTEI Grant




Incorporation



Clinical Validation



Regulation — 510(k)



Revenue
Devices

2026
\$330K
180

2027
\$3.1M
400

2028
\$16M
12.8K

2029
\$68M
40.9K

2030
\$144M
59.1K

Help Us Reshape the Future of Healthcare

